Found 733 events where Vaccine is VARZOS and Serious

VAERS ID: 293405 (history)   Vaccinated: 2007-04-16 Age: 72.0   Onset: 2007-10-05, Days after vaccination: 172 Gender: Female   Submitted: 2007-10-16, Days after onset: 11 Location: Texas   Entered: 2007-10-17, Days after submission: 1	Life Threatening? No Died? No Permanent Disability? Yes Recovered? No ER or Doctor Visit? Yes Hospitalized? No Previous Vaccinations: Other Medications: VYTORIN Current Illness: Penicillin allergy Preexisting Conditions: Diagnostic Lab Data: None CDC 'Split Type': WAES0710USA02539
Vaccination Manufacturer Lot Dose Route Site VARZOS: ZOSTER (ZOSTAVAX) MERCK & CO. INC. 1476F   SC UN
Administered by: Other     Purchased by: Other Symptoms: Herpes zoster, Pain SMQs: Write-up: Information has been received from a physician concerning a 73 year old female with no medical history and penicillin allergy who on 16-APR-2007 was vaccinated SC on right arm with a single dose of Zostavax (Oka/Merck) (Lot 3 656412/1476F). Concomitant therapy included 10mg/20 mg once daily ezetimibe (+) simvastatin (MSD). On 05-OCT-2007 the patient developed shingles on her "bottom" which was described very painful to sit. The patient was prescribed valacyclovir hydrochloride (VALTREX), prednisone and hydrocodone for her symptoms. No diagnostic laboratory tests were undertaken. At the time of report the patient had not recovered. A product quality complaint was not involved. The patient''s experience was considered to be disabling by the reporter. Additional information has been requested.
VAERS ID: 293571 (history)   Vaccinated: 2007-08-30 Age:    Onset: 2007-10-05, Days after vaccination: 36 Gender: Female   Submitted: 2007-10-17, Days after onset: 12 Location: Florida   Entered: 2007-10-18, Days after submission: 1	Life Threatening? No Died? No Permanent Disability? No Recovered? No ER or Doctor Visit? Yes Hospitalized? No Previous Vaccinations: Other Medications: Unknown Current Illness: Preexisting Conditions: Unknown Diagnostic Lab Data: Unknown CDC 'Split Type': WAES0710USA02991
Vaccination Manufacturer Lot Dose Route Site VARZOS: ZOSTER (ZOSTAVAX) MERCK & CO. INC.     UN UN
Administered by: Other     Purchased by: Other Symptoms: Guillain-Barre syndrome, Muscular weakness, Musculoskeletal pain SMQs:, Rhabdomyolysis/myopathy (broad), Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Noninfectious encephalopathy/delirium (broad), Demyelination (narrow) Write-up: Information has been received from a physician concerning a female (age not reported) who on approximately 30-AUG-2007 "6 weeks ago" was vaccinated with Zostavax (Oka/Merck). On approximately 05-OCT-2007 "one week ago", the patient experienced pain in the buttocks to weakness to the lower extremities. The physician believes the patient may have Guillain-Barre Syndrome. The patient''s experience caused hospitalization. At the time of the report, the patient remained hospitalized. Additional information has been requested.
VAERS ID: 293741 (history)   Vaccinated: 2007-09-19 Age: 66.0   Onset: 2007-09-21, Days after vaccination: 2 Gender: Male   Submitted: 2007-10-18, Days after onset: 27 Location: Florida   Entered: 2007-10-19, Days after submission: 1	Life Threatening? No Died? No Permanent Disability? Yes Recovered? No ER or Doctor Visit? No Hospitalized? No Previous Vaccinations: Other Medications: LOTREL; ZOCOR Current Illness: Iodine allergy; Penicillin allergy Preexisting Conditions: Diagnostic Lab Data: None CDC 'Split Type': WAES0710USA03094
Vaccination Manufacturer Lot Dose Route Site VARZOS: ZOSTER (ZOSTAVAX) MERCK & CO. INC.     UN UN
Administered by: Other     Purchased by: Other Symptoms: Deafness, Exposure to communicable disease, Pharyngolaryngeal pain, Pyrexia, Rash, Swelling face, Varicella SMQs:, Anaphylactic reaction (broad), Angioedema (narrow), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Hearing impairment (narrow), Hypersensitivity (narrow) Write-up: Information has been received from a 66 year old male medical technologist with no pertinent medical history, and an allergy to both iodine and penicillin who on 19-SEP-2007 was vaccinated with Zostavax (Oka/Merck). Concomitant therapy included simvastatin (MSD) and amlodipine besylate (+) benazepril hydrochloride (LOTREL). The patient reported that on 21-SEP-2007, two days after administration of Zostavax (Oka/Merck), he developed chickenpox. The patient reported developing a "a rash" on his face, scalp, chest, hands, feet, throat and ears. The patient also reported having a high fever, sore throat, a swollen face and some hearing loss. The patient noted he had been exposed to zoster from his wife two weeks prior to his outbreak. The patient reported that on 01 OCT 2007 he had recovered from all of his symptoms, except for his hearing loss. Medical attention was sought via telephone. There were no lab diagnostic studies performed. There was no product quality complaint. The reporter considered the adverse events to be disabling. Additional information has been requested.
VAERS ID: 294219 (history)   Vaccinated: 0000-00-00 Age: 80.0   Onset: 2007-10-16 Gender: Male   Submitted: 2007-10-23, Days after onset: 7 Location: Unknown   Entered: 2007-10-24, Days after submission: 1	Life Threatening? No Died? No Permanent Disability? Yes Recovered? No ER or Doctor Visit? Yes Hospitalized? No Previous Vaccinations: Other Medications: Unknown Current Illness: Immune system disorder Preexisting Conditions: Diagnostic Lab Data: Unknown CDC 'Split Type': WAES0710USA03513
Vaccination Manufacturer Lot Dose Route Site VARZOS: ZOSTER (ZOSTAVAX) MERCK & CO. INC.     UN UN
Administered by: Other     Purchased by: Other Symptoms: Herpes zoster, Secondary transmission SMQs: Write-up: Information has been received from a registered nurse concerning an approximately 80 or 90 year old immunocompromised male who was in the same room where the other residents of the retirement community where vaccinated with a dose of Zostavax (Oka/Merck). It was reported that the patient had spouse or contact (s) who lived in the independent residence within the community and who were vaccinated with a dose of Zostavax (MSD). The patient was not vaccinated with the vaccine. On 16-OCT-2007 the patient developed shingles. At the time of report the patient had not recovered. The patient''s experience was considered to be an other important medical event and disabling by the reporter. Additional information has been requested. This is one of several reports received from the same source.
VAERS ID: 294220 (history)   Vaccinated: 0000-00-00 Age: 80.0   Onset: 2007-10-16 Gender: Male   Submitted: 2007-10-23, Days after onset: 7 Location: Unknown   Entered: 2007-10-24, Days after submission: 1	Life Threatening? Yes Died? No Permanent Disability? Yes Recovered? No ER or Doctor Visit? Yes Hospitalized? No Previous Vaccinations: Other Medications: Unknown Current Illness: Living in care; Immune system disorder Preexisting Conditions: Diagnostic Lab Data: Unknown CDC 'Split Type': WAES0710USA03512
Vaccination Manufacturer Lot Dose Route Site VARZOS: ZOSTER (ZOSTAVAX) MERCK & CO. INC.     UN UN
Administered by: Other     Purchased by: Other Symptoms: Herpes zoster, Secondary transmission SMQs: Write-up: Information has been received from a registered nurse concerning an approximately 80 or 90 year old immunocompromised male who was in hospice care who was in the same room where the other residents of the retirement community were vaccinated with a dose of Zostavax (Oka/Merck). It was reported that the patient had a spouse or contact (s) who lived in the independent residences within the community and who were vaccinated with a dose of Zostavax vaccine (MSD). The patient was not vaccinated with the vaccine. On 16-OCT-2007 the patient developed shingles. At the time of report the patient had not recovered. The patient''s experience was considered to be life threatening, an other important medical event and disabling by the reporter. Additional information has been requested. This is one of several reports received from the same source.
VAERS ID: 294221 (history)   Vaccinated: 0000-00-00 Age: 80.0   Onset: 2007-10-10 Gender: Female   Submitted: 2007-10-23, Days after onset: 13 Location: Unknown   Entered: 2007-10-24, Days after submission: 1	Life Threatening? No Died? No Permanent Disability? Yes Recovered? No ER or Doctor Visit? Yes Hospitalized? No Previous Vaccinations: Other Medications: Unknown Current Illness: Immune system disorder Preexisting Conditions: Diagnostic Lab Data: Unknown CDC 'Split Type': WAES0710USA03511
Vaccination Manufacturer Lot Dose Route Site VARZOS: ZOSTER (ZOSTAVAX) MERCK & CO. INC.     UN UN
Administered by: Other     Purchased by: Other Symptoms: Herpes zoster, Secondary transmission SMQs: Write-up: Information has been received from a registered nurse concerning an approximately 80 or 90 year old immunocompromised female who was in the same room where the other residents of the retirement community were vaccinated with a dose of Zostavax (Oka/Merck). It was reported that the patient had spouses or contact (s) who lived in the independent residences within the community and who were vaccinated with a dose of Zostavax (MSD). The patient was not vaccinated with the vaccine. On 10-OCT-2007 the patient developed shingles. At the time of report the patient had not recovered. The patient''s experience was considered to be an other important medical event and disabling by the reporter. Additional information has been requested. This is one of several reports received from the same source.
VAERS ID: 294222 (history)   Vaccinated: 0000-00-00 Age: 80.0   Onset: 2007-10-09 Gender: Female   Submitted: 2007-10-23, Days after onset: 14 Location: Unknown   Entered: 2007-10-24, Days after submission: 1	Life Threatening? No Died? No Permanent Disability? Yes Recovered? No ER or Doctor Visit? Yes Hospitalized? No Previous Vaccinations: Other Medications: Unknown Current Illness: Immune system disorder Preexisting Conditions: Diagnostic Lab Data: None CDC 'Split Type': WAES0710USA03448
Vaccination Manufacturer Lot Dose Route Site VARZOS: ZOSTER (ZOSTAVAX) MERCK & CO. INC.     UN UN
Administered by: Other     Purchased by: Other Symptoms: Herpes zoster, Infection, Secondary transmission, Skin lesion SMQs: Write-up: Information has been received from a registered nurse concerning an approximately 80 or 90 year old immunocompromised female who was in the same room where the other residents of the retirement community were vaccinated with a dose of Zostavax (Oka/Merck). It was reported that the patient had spouse of contact (s) who lived in the independent residences within the community and who were vaccinated with a dose of Zostavax (MSD). The patient was not vaccinated with the vaccine. On approximately 09-OCT-2007 the patient developed shingles and had lesions on the back of the scalp. The patient was treated with valacyclovir hydrochloride (VALTREX) but the scalp area got infected and was draining so the resident was sent to the hospital. The patient was put on IV vancomycin. At the time of report the patient had not recovered. The patient''s experience was considered to be an other important medical event and disabling by the reporter. Additional information has been requested. This is one of several reports received from the same source.
VAERS ID: 294235 (history)   Vaccinated: 2007-03-23 Age: 72.0   Onset: 2007-04-06, Days after vaccination: 14 Gender: Female   Submitted: 2007-10-17, Days after onset: 194 Location: Georga   Entered: 2007-10-24, Days after submission: 7	Life Threatening? No Died? No Permanent Disability? No Recovered? Yes ER or Doctor Visit? No Hospitalized? No Previous Vaccinations: Other Medications: EFFEXOR; ATACAND; ACTOS; PREVACID; CELEBREX; lantus; METFORMIN; aspirin Current Illness: Shingles ? Preexisting Conditions: Type 2 diabetes; Hypertension; GERD; Chronic back pain; neurogenic bladder with prior surgery in 2005 1/28/08-records received-HX of recurrent urinary tract infections. Hypertension. Diabetes, Gastroesophageal reflux disease, chronic back pain. Diagnostic Lab Data: VZV and VDRL and HSV in spinal fluid -; HSV PCR 9-), patient afebrile, did not have leukocytosis 1/28/08-records received- Blood culture positive for polymicrobial sepsis including Pseudomonas species, E. coli and Proteus. CDC 'Split Type':
Vaccination Manufacturer Lot Dose Route Site VARZOS: ZOSTER (ZOSTAVAX) MERCK & CO. INC.   1 UN UN
Administered by: Private     Purchased by: Other Symptoms: Abdominal pain, Aphasia, CSF test normal, Chills, Confusional state, Dysphagia, Encephalitis, Encephalopathy, Escherichia infection, Hallucination, Herpes zoster, Mental status changes, Neurogenic bladder, Polymerase chain reaction, Proteus infection, Pruritus, Pseudomonal sepsis, Pyrexia, Sepsis, Syphilis test negative, Urinary tract infection SMQs:, Anaphylactic reaction (broad), Acute pancreatitis (broad), Agranulocytosis (broad), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Retroperitoneal fibrosis (broad), Dementia (broad), Psychosis and psychotic disorders (narrow), Guillain-Barre syndrome (broad), Noninfectious encephalitis (narrow), Noninfectious encephalopathy/delirium (narrow), Noninfectious meningitis (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Cardiomyopathy (broad), Conditions associated with central nervous system haemorrhages and cerebrovascular accidents (broad), Chronic kidney disease (broad), Hypersensitivity (broad) Write-up: Pt found to have dysphagia/confusion. Exact time of onset of s/s are unknown. Pt admitted to ED where stroke was ruled out. Pt continued to have changes in mental status/hallucinations. Pt also with lesions consistent with shingles. Pt diagnosed with encephalitis. Started on IV Acyclovir. Encephalopathy resolving after starting Acyclovir. Pt with possible VZV encephalitis that has markedly improved with continuing 14 days of IV Acyclovir. 1/28/08-records received-for DOS 4/6-4/18/07 and 4/29-5/4/07-DX: probable varicella zoster viurs encephalitis. E. coli urinary tract infection. Neurogenic bladder. Polymicrobial sepsis, resolving. Presented to ED with confusion and global aphasia. Shingles. Pruritus. Fever chills and abdominal pain.
VAERS ID: 294544 (history)   Vaccinated: 2007-08-01 Age: 61.0   Onset: 2007-09-30, Days after vaccination: 60 Gender: Female   Submitted: 2007-10-25, Days after onset: 25 Location: Georga   Entered: 2007-10-27, Days after submission: 2	Life Threatening? Yes Died? No Permanent Disability? Yes Recovered? No ER or Doctor Visit? Yes Hospitalized? No Previous Vaccinations: Other Medications: ZYRTEC; EPI-PEN; ZANTAC Current Illness: Preexisting Conditions: None Diagnostic Lab Data: laboratory test - full biochemistry; laboratory test - electrolytes abnormalities; lymphocyte count 63-64 CDC 'Split Type': WAES0710USA03927
Vaccination Manufacturer Lot Dose Route Site VARZOS: ZOSTER (ZOSTAVAX) MERCK & CO. INC.     UN UN
Administered by: Other     Purchased by: Other Symptoms: Anaphylactic reaction, Electrolyte imbalance, Laboratory test, Laboratory test abnormal, Laryngeal oedema, Lymphocyte count increased, Urticaria SMQs:, Anaphylactic reaction (narrow), Angioedema (narrow), Anaphylactic/anaphylactoid shock conditions (narrow), Hypersensitivity (narrow) Write-up: Information has been received from a physician concerning a female with no pertinent medical history or drug allergies who on approximately 01-AUG-2007 was vaccinated with a dose of Zostavax (Oka/Merck) in the deltoid. Concomitant drug therapy included cetrizine hydrochloride (ZYRTEC), ranitidine HCl (ZANTAC) and epinephrine (EPI-PEN). On approximately 30-SEP-2007 the patient experienced anaphylaxis characterized by chronic hives primarily on the extremities and swelling of the laryngeal area. The physician was consulted and the patient and was subsequently hospitalized for 4-5 days. Epinephrine was administered to treat the reaction. The patient was also treated with steroids for awhile. Lab diagnostic studies performed included full biochemistry labs at the hospital, electrolyte test revealing abnormalities, and a 63-64 value for lymphocyte count. The patient was noted to functional but not recovered. There was no product quality complaint. The physician considered hives and laryngeal swelling to be immediately life-threatening, disabling and an other important medical event. Additional information has been requested.
VAERS ID: 294545 (history)   Vaccinated: 2007-10-11 Age: 67.0   Onset: 2007-10-11, Days after vaccination: 0 Gender: Female   Submitted: 2007-10-25, Days after onset: 14 Location: Michigan   Entered: 2007-10-27, Days after submission: 2	Life Threatening? Yes Died? No Permanent Disability? No Recovered? No ER or Doctor Visit? No Hospitalized? No Previous Vaccinations: Other Medications: Unknown Current Illness: Preexisting Conditions: Unknown PMH: diverticulitis, colectomy. spinal stenosis & lumbar disk disease. Arthritis. Hypothyroid. Vit D deficiency. ALLERGIES: levaquin, sulfa & demerol. Diagnostic Lab Data: Unknown LABS: CT & MRI head WNL. CT abdomen/pelvis. CBC WNL. TSH 0.06 (L). Ammonia 11 (L). 10/18 CSF: glucose 108, protein 255, csf culture neg. WBC 8,200, segs 67, lymphs 24. UA (+) nitrite. Urine culture (+) E. coli. EEG abnormal. CDC 'Split Type': WAES0710USA04429
Vaccination Manufacturer Lot Dose Route Site PPV: PNEUMO (PNEUMOVAX) MERCK & CO. INC. 0964U   IM LA VARZOS: ZOSTER (ZOSTAVAX) MERCK & CO. INC. 0883U   SC LA
Administered by: Other     Purchased by: Other Symptoms: Ammonia decreased, Asthenia, Balance disorder, Blood thyroid stimulating hormone decreased, CSF culture negative, CSF glucose increased, CSF protein increased, Computerised tomogram normal, Culture urine positive, Diverticulitis, Dyspnoea, Electroencephalogram abnormal, Encephalitis, Encephalopathy, Escherichia infection, Full blood count normal, Gastrointestinal tube insertion, Injection site erythema, Injection site streaking, Injection site swelling, Intensive care, Malaise, Nuclear magnetic resonance imaging brain normal, Pain, Pyrexia, Speech disorder, Urinary tract infection, Urine analysis abnormal SMQs:, Anaphylactic reaction (broad), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Dementia (broad), Acute central respiratory depression (broad), Psychosis and psychotic disorders (broad), Pulmonary hypertension (broad), Guillain-Barre syndrome (broad), Noninfectious encephalitis (narrow), Noninfectious encephalopathy/delirium (narrow), Extravasation events (injections, infusions and implants) (broad), Gastrointestinal nonspecific inflammation (broad), Haemodynamic oedema, effusions and fluid overload (narrow), Cardiomyopathy (broad), Hypothyroidism (broad), Hyperthyroidism (broad), Vestibular disorders (broad), Chronic kidney disease (broad) Write-up: Information has been received from a physician concerning a 67 year old female who on 11-OCT-2007 was vaccinated with a dose of Zostavax (Oka/Merck) (lot# 658207/0883U). In October 2007, the patient developed encephalitis. On 16-OCT-2007 the patient was admitted to the hospital. The patient was treated with steroids and acyclovir. The patient''s encephalitis persisted. There was no product quality complaint. The physician considered encephalitis to be immediately life-threatening and an other important medical event. Additional information has been requested. 10/30/07 Follow up initiated at request of CDC. 11/16/07 Reviewed hospital & pcp medical records which also included vax info. VAERS database updated w/same. Records reveal patient experienced trouble talking, body aches, weakness, balance difficulty, SOB, malaise & fever x 2-3 days. Admitted 10/16-10/30/2007 & then to swing bed from 10/30-11/1/07. LP done. Had seen her pcp 10/11 w/complaints of LLQ abdominal pain, diarrhea, nausea & back/left leg pain. Started on oral antibiotics at that time for diverticulitis & received zoster & pneumo vax that day. On 10/15 left arm very red & swollen w/red streaking by phone & instructed to apply ice.Apparently had word retrieval difficulty beginning 2 days s/p vax. Neuro consult. Tx w/IV antibiotics & antiviral. Tx w/steroids & antiseizure meds & transferred to ICU. PICC & feeding tube inserted. FINAL DX: Encephalopathy; UTI.